4A1.F CERENO SCIENTIFIC AB B

Healthcare Pharmaceuticals Frankfurt Exchange
0.1654 EUR
Close of Nov 5, 2026
0.1590 0.7825
Market cap
EUR 53.4M
P/E
-
P/B
2.56x
ROE
-50.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 4A1.F undervalued?

Graham number

The Graham number of CERENO SCIENTIFIC AB B cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CERENO SCIENTIFIC AB B fundamental analysis

No fundamental analysis for CERENO SCIENTIFIC AB B yet.

CERENO SCIENTIFIC AB B stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CERENO SCIENTIFIC AB B

Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue rem…

Full company profile